Top

Published in:

Open Access 01-12-2018 | Case report

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review

Authors: Philippe Rochigneux, Jeanne Thomassin-Piana, Sophy Laibe, Serge Brunelle, Naji Salem, Bernard Escudier, Gilles Vassal, Gwenaelle Gravis

Published in: BMC Cancer | Issue 1/2018

Abstract

Background

Papillary renal cell carcinoma (pRCC) is the 2nd most frequent histological type of kidney cancer and accounts for approximately 15% of all renal cell carcinoma. It has a poorer prognosis than clear cell RCC (ccRCC) with a lack of standard treatments.

Case presentation

We report the case of a 51 year old man with a metastatic pRCC (hepatic dome and left colonic peritoneal carcinomatosis) progressive after sunitinib, with a MET amplification. The patient was enrolled in the UNICANCER-sponsored AcSé crizotinib trial (NCT02034981), designed to give an access to crizotinib for patients with tumors harboring a genomic alteration on one of the biological targets of the drug. With 2nd line crizotinib (250 mg twice/day), the patient had a very good tolerance, a partial response in the target lesions using RECIST 1.1, and a 19 months’ clinical efficacy.

Conclusions

In metastatic pRCC with a MET amplification, crizotinib maybe a potential met-inhibitory therapeutic option.

Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26:127–31.CrossRef

Ravaud A, Oudard S, De Fromont M, et al. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG). Ann Oncol. 2015;26:1123–8.CrossRef

NCCN. NCCN clinical practice guidelines in oncology-kidney cancer. Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. [cited 30 Jan 2017].

Appleman LJ. MET signaling pathway: a rational target for cancer therapy. J Clin Oncol. 2011;29:4837–8.CrossRef

Petrini I. Biology of MET: a double life between normal tissue repair and tumor progression. Ann Transl Med. 2015;3:82.PubMedPubMedCentral

Buzyn A, Blay J-Y, Hoog-Labouret N, et al. Equal access to innovative therapies and precision cancer care. Nat Rev Clin Oncol. 2016;13:385–93.CrossRef

Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17:378–88.CrossRef

Tannir NM, Jonasch E, Albiges L, et al. Everolimus versus sunitinib prospective evaluation in metastatic non–clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol. 2016;69:866–74.CrossRef

Matrana MR, Baiomy A, Campbell M, Alamri S, Shetty A, Teegavarapu P, Kalra S, et al. Outcomes of patients with metastatic non–clear-cell renal cell carcinoma treated with pazopanib. Clin Genitourin Cancer. 2017;15(2).CrossRef

10.

Diamond JR, Salgia R, Varella-Garcia M, et al. Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. J Clin Oncol. 2013;31:e254–8.CrossRef

11.

Albiges L, Guegan J, Formal AL, et al. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. Clin Cancer Res. 2014;20:3411–21.CrossRef

12.

Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16:68–73.CrossRef

13.

Glukhova L, Lavialle C, Fauvet D, et al. Mapping of the 7q31 subregion common to the small chromosome 7 derivatives from two sporadic papillary renal cell carcinomas: increased copy number and overexpression of the MET proto-oncogene. Oncogene. 2000;19:754–61.CrossRef

14.

The Cancer Genome Atlas Research. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med. 2016;374:135–45.CrossRef

15.

Ciccarese C, Massari F, Santoni M, et al. New molecular targets in non clear renal cell carcinoma: an overview of ongoing clinical trials. Cancer Treat Rev. 2015;41:614–22.CrossRef

16.

Garajová I, Giovannetti E, Biasco G, et al. c-Met as a target for personalized therapy. Transl Oncogenomics. 2015;7:13–31.PubMedPubMedCentral

17.

Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31:181–6.CrossRef

18.

Twardowski P, Plets M. SWOG 1107: parallel (randomized) phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (Pts) with papillary renal cell carcinoma (pRCC). J Clin Oncol:33(15_suppl). Available from: http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.4523. [cited 11 Oct 2018].

19.

Choueiri TK, Plimack E, Arkenau H-T, et al. Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer. J Clin Oncol. 2017;35:2993–3001.CrossRef

20.

Cabozantinib s-malate, crizotinib, volitinib, or sunitinib malate in treating patients with locally advanced or metastatic kidney cancer - Full Text View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02761057. [cited 11 Oct 2018].

21.

Shaw AT, S-HI O, Bang Y-J, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963–71.

22.

Shaw AT, Kim D-W, Nakagawa K, Seto T, Crinó L, Ahn M-J, De Pas T, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94.CrossRef

23.

Stein MN, Hirshfield KM, Zhong H, et al. Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib. Eur Urol. 2015;67:353–4.CrossRef

24.

Schöffski P, Wozniak A, Escudier B, et al. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. Eur J Cancer. 2017;87:147–63.CrossRef

25.

ClinicalTrials: phase 2 study assessing efficacy and safety of crizotinib in patients harboring an alteration on ALK, MET or ROS1 - Tabular View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02034981. [cited 10 Feb 2017].

26.

Vassal G. Meeting Library | Biomarker-driven access to crizotinib in ALK, MET, or ROS1 positive (+) malignancies in adults and children: The French National AcSé Program. Available from: https://meetinglibrary.asco.org/record/158633/abstract. [cited 12 Oct 2018].

27.

Aparicio T. Meeting Library | The activity of crizotinib in chemo-refractory MET-amplified esogastric adenocarcinomas: results from the AcSé-crizotinib program. Available from: https://meetinglibrary.asco.org/record/160162/abstract. [cited 12 Oct 2018].

Title: Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review
Authors: Philippe Rochigneux
Jeanne Thomassin-Piana
Sophy Laibe
Serge Brunelle
Naji Salem
Bernard Escudier
Gilles Vassal
Gwenaelle Gravis
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-018-5049-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study

What is it about a cancer diagnosis that would worry people? A population-based survey of adults in England

CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy

Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis

FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients

A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer